[go: up one dir, main page]

AR086688A2 - Composicion farmaceutica con excipiente liquido modificado, un metodo para producir una composicion farmaceutica y el uso de dicha composicion para preparar un medicamento - Google Patents

Composicion farmaceutica con excipiente liquido modificado, un metodo para producir una composicion farmaceutica y el uso de dicha composicion para preparar un medicamento

Info

Publication number
AR086688A2
AR086688A2 ARP120101998A ARP120101998A AR086688A2 AR 086688 A2 AR086688 A2 AR 086688A2 AR P120101998 A ARP120101998 A AR P120101998A AR P120101998 A ARP120101998 A AR P120101998A AR 086688 A2 AR086688 A2 AR 086688A2
Authority
AR
Argentina
Prior art keywords
composition
pharmaceutical composition
liquid carrier
producing
oil
Prior art date
Application number
ARP120101998A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of AR086688A2 publication Critical patent/AR086688A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Una composición farmacéutica que comprende: (a) uno o más agentes biológicamente activos; y (b) un excipiente líquido modificado; en donde se proporciona una composición que inmediatamente después de fabricada puede administrarse a un huésped de manera tal que uno o más agentes biológicamente activos se liberan al huésped en forma continua y predecible; un método para producir una composición farmacéutica y el uso de dicha composición para preparar un medicamento para tratar o prevenir una enfermedad en un mamífero.Reivindicación 1: Una composición farmacéutica caracterizada porque comprende: (a) ácido libre de ceftiofur cristalino; y (b) un portador líquido, dicho portador líquido comprende un aceite insaturado que tiene un valor de peróxido de entre 0.1 y 600 miliequivalentes (mEq) de peróxido por 1000 gramos de aceite. Reivindicación 2: La composición según la reivindicación 1 caracterizada porque dicho portador líquido comprende una mezcla de un aceite insaturado con un aceite saturado. Reivindicación 8: La composición de la reivindicación 1, caracterizada porque dicho portador líquido comprende una mezcla de dicho aceite insaturado con un vehículo no oxidante.
ARP120101998A 2000-09-12 2012-06-06 Composicion farmaceutica con excipiente liquido modificado, un metodo para producir una composicion farmaceutica y el uso de dicha composicion para preparar un medicamento AR086688A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23176700P 2000-09-12 2000-09-12

Publications (1)

Publication Number Publication Date
AR086688A2 true AR086688A2 (es) 2014-01-15

Family

ID=22870572

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP010104286A AR030648A1 (es) 2000-09-12 2001-09-11 Composicion farmaceutica con excipiente modificado
ARP120101998A AR086688A2 (es) 2000-09-12 2012-06-06 Composicion farmaceutica con excipiente liquido modificado, un metodo para producir una composicion farmaceutica y el uso de dicha composicion para preparar un medicamento

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP010104286A AR030648A1 (es) 2000-09-12 2001-09-11 Composicion farmaceutica con excipiente modificado

Country Status (18)

Country Link
US (1) US20020110561A1 (es)
EP (1) EP1317256B1 (es)
JP (1) JP4738713B2 (es)
AR (2) AR030648A1 (es)
AT (1) ATE412405T1 (es)
AU (2) AU8832301A (es)
BR (1) BRPI0113372B8 (es)
CA (1) CA2416566C (es)
DE (1) DE60136367D1 (es)
DK (1) DK1317256T3 (es)
ES (1) ES2313981T3 (es)
MX (1) MXPA03002055A (es)
NZ (1) NZ524694A (es)
PE (1) PE20030046A1 (es)
PT (1) PT1317256E (es)
TW (1) TWI284046B (es)
WO (1) WO2002022107A2 (es)
ZA (1) ZA200300617B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033938A1 (en) * 2000-09-12 2004-02-19 Britten Nancy J. Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
KR20040015622A (ko) * 2002-08-13 2004-02-19 대한뉴팜(주) 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물
US7659061B2 (en) * 2002-11-19 2010-02-09 Pharmacia & Upjohn Company Pharmaceutical compositions having a modified vehicle
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
US20080153894A1 (en) * 2002-12-19 2008-06-26 Pharmacia Corporation Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
CA2743551C (en) * 2008-11-19 2017-08-15 Merial Limited Formulations comprising ceftiofur and ketoprofen or ceftiofur and benzyl alcohol
BRPI0903778B1 (pt) 2009-07-17 2017-04-18 Cargill Agrícola S A composição alimentícia de gordura vegetal, processo de preparação de uma composição alimentícia de gordura vegetal e uso de uma composição alimentícia de gordura vegetal na preparação de recheio
MX340951B (es) * 2011-09-29 2016-07-29 Plx Pharma Inc Portadores dependientes del ph para la liberacion dirigida de productos farmaceuticos a lo largo del tracto gastrointestinal, composiciones de los mismos, y fabricación y uso de las mismas.
CA2968320A1 (en) 2014-11-19 2016-05-26 Cassandra K JONES Chemical mitigants in animal feed and feed ingredients
PH12021551973A1 (en) 2019-03-06 2022-05-23 Zoetis Services Llc Ready-to-use injectable formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122005000055I2 (de) * 1993-03-12 2008-06-05 Upjohn Co Kristallines ceftiofur (freie säure)
US5736151A (en) * 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
US6074657A (en) * 1997-03-20 2000-06-13 Pharmacia & Upjohn Company Administration of an injectable antibiotic in the ear of an animal

Also Published As

Publication number Publication date
US20020110561A1 (en) 2002-08-15
CA2416566C (en) 2011-05-31
BRPI0113372B1 (pt) 2017-08-01
NZ524694A (en) 2005-05-27
JP2004508395A (ja) 2004-03-18
PT1317256E (pt) 2008-12-17
EP1317256A2 (en) 2003-06-11
CA2416566A1 (en) 2002-03-21
JP4738713B2 (ja) 2011-08-03
DE60136367D1 (de) 2008-12-11
EP1317256B1 (en) 2008-10-29
ATE412405T1 (de) 2008-11-15
AU2001288323B2 (en) 2006-11-23
ZA200300617B (en) 2004-04-22
ES2313981T3 (es) 2009-03-16
BRPI0113372A8 (es) 2003-06-24
BRPI0113372B8 (pt) 2021-10-13
PE20030046A1 (es) 2003-02-14
MXPA03002055A (es) 2004-12-13
DK1317256T3 (da) 2009-01-26
TWI284046B (en) 2007-07-21
AU8832301A (en) 2002-03-26
WO2002022107A2 (en) 2002-03-21
WO2002022107A3 (en) 2003-01-16
AR030648A1 (es) 2003-08-27
BR0113372A (pt) 2003-06-24

Similar Documents

Publication Publication Date Title
AR086688A2 (es) Composicion farmaceutica con excipiente liquido modificado, un metodo para producir una composicion farmaceutica y el uso de dicha composicion para preparar un medicamento
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
ES2091441T3 (es) Composicion farmaceutica.
MX9304485A (es) Formulacion solida, oral, de liberacion controlada, que incluye complejos hidrofilicos aglomerados con caracteristicas de liberacion multifasicas.
BR0111016A (pt) Composições farmacêuticas de liberação sustentada para a administração parenteral de compostos hidrófilos biologicamente ativos
UY25799A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina y otro agente antidiabético.
BR9808888A (pt) Formas de dosagem e método de melhorar disfunção erétil masculina
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
BRPI9913945B8 (pt) Composição farmacêutica rapidamente atuante para a administração sublingual de um agente farmacêutico para o tratamento de distúrbios agudos
AR026165A1 (es) Dispositivo para la administracion de drogas.
SV2002000969A (es) Composicion parenteral reconstituible
BR9913948A (pt) Composição farmacêutica para o tratamento de dor aguda por administração sublingual, uso de fentanila ou um sal farmaceuticamente aceitável da mesma, e processo para o tratamento de dor aguda
ES2137350T3 (es) Formulacion farmaceutica.
ES2185758T3 (es) Utilizacion de esteres grasos etoxilados como compuestos auto-emulsionables.
ES2130217T3 (es) Uso de tiloxapol como dispersante y estabilizante de nanoparticulas.
ES2159591T3 (es) Composicion de liberacion controlada.
BR9206593A (pt) Partículas especialmente partículas coloidais processo de prepará-las a partir de uma fase cristalina líquida homogênea ou fase L3 composição farmacêutica e uso destas partículas
AR043863A1 (es) Composiciones que contienen piperacilina y tazobactam, utiles para inyeccioines
ES2249197T1 (es) Formulaciones de adhesivo de silicona con base de suspension de fentanilo y dispositivos para la administracion transdermica de fentanilo.
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
BR0017268A (pt) Composição farmacêutica de propofol, aquosa, lìmpida, estável na esterilização em autoclave, apropriada para administração parenteral, e processo para a preparação de uma composição farmacêutica de propofol, aquosa, lìmpida, estável na esterilização em autoclave, apropriada para administração parenteral
AR008355A1 (es) COMPOSICIoN FARMACÉUTICA PARA ADMINISTRACIoN ORAL, USO, CREMA FARMACEUTICA PARA ADMINISTRACIoN TOPICA Y SUSPENSIoN LIQUIDA PARA ADMINISTRACIoN ORAL.
BR9916114A (pt) Uso de apomorfina na fabricação de um medicamento para tratamento de disfunção erétil orgânica masculina
BR0107899A (pt) Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida
ES2099021B1 (es) Composicion farmaceutica que tiene actividad analgesica.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal